Related Experiment Video
Updated: Oct 21, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Rare complication of ceftriaxone therapy: drug-induced thrombocytopenia (DITP)
Aishwarya Sharma1, Devendranath Mannuru2,3, Abhishek Matta2,3
1School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota, USA aishwaryasharma97@gmail.com.
Abstract:
A 62-year-old woman with a history of end-stage renal disease on haemodialysis, essential hypertension and type 2 diabetes mellitus was diagnosed with sepsis and placed on 600 mg oral linezolid every 12 hours and 1 g intravenous ceftriaxone every 24 hours. Blood cultures grew Streptococcus dysgalactiae, and she was switched to intravenous ceftriaxone 2 g daily. Platelet counts slowly trended down after starting ceftriaxone reaching 5 K/μL on day 12 of treatment. Ceftriaxone was discontinued and heparin-induced thrombocytopaenia was ruled out. She was switched to vancomycin and her platelet count improved. Given the temporal relationship between changing platelet counts and starting and discontinuing ceftriaxone, a diagnosis of drug-induced thrombocytopaenia was made.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmacokinetics: Drug–Drug Interactions
Venous Thrombosis III: Interprofessional Care
Desensitization and Tachyphylaxis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...

